Dimerix Partners with UK's Rare Kidney Disease Registry for Recruitment for ACTION3 Phase Three Clinical Trial

MT Newswires Live

Sep 16, 2024

Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse.

The trial aims to assess the efficacy and safety of the biopharmaceutical company's DMX-200 in treating a rare kidney condition called Focal Segmental Glomerulosclerosis, the filing stated. Recruitment is being done across 16 of the 19 planned countries, with a total recruitment target of 286 patients.

Additionally, Dimerix received approval for its Investigational New Drug Application from the Thai Food and Drug Administration, clearing a prerequisite for trial initiation. It expects clinical sites to begin recruitment in Thailand in the coming weeks.

The company's shares slipped past 1% in recent Monday trade.

Price (AUD): $0.41, Change: $-0.01, Percent Change: -1.20%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2467168865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2467168865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2467168865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-16 11:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467168865","market":"sh","top_or_hot":-1,"title":"Dimerix Partners with UK's Rare Kidney Disease Registry for Recruitment for ACTION3 Phase Three Clinical Trial","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse.</p><p>The trial aims to assess the efficacy and safety of the biopharmaceutical company's DMX-200 in treating a rare kidney condition called Focal Segmental Glomerulosclerosis, the filing stated. Recruitment is being done across 16 of the 19 planned countries, with a total recruitment target of 286 patients.</p><p>Additionally, Dimerix received approval for its Investigational New Drug Application from the Thai Food and Drug Administration, clearing a prerequisite for trial initiation. It expects clinical sites to begin recruitment in Thailand in the coming weeks.</p><p>The company's shares slipped past 1% in recent Monday trade.</p><p>Price (AUD): $0.41, Change: $-0.01, Percent Change: -1.20%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Partners with UK's Rare Kidney Disease Registry for Recruitment for ACTION3 Phase Three Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Partners with UK's Rare Kidney Disease Registry for Recruitment for ACTION3 Phase Three Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-16 11:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse.</p><p>The trial aims to assess the efficacy and safety of the biopharmaceutical company's DMX-200 in treating a rare kidney condition called Focal Segmental Glomerulosclerosis, the filing stated. Recruitment is being done across 16 of the 19 planned countries, with a total recruitment target of 286 patients.</p><p>Additionally, Dimerix received approval for its Investigational New Drug Application from the Thai Food and Drug Administration, clearing a prerequisite for trial initiation. It expects clinical sites to begin recruitment in Thailand in the coming weeks.</p><p>The company's shares slipped past 1% in recent Monday trade.</p><p>Price (AUD): $0.41, Change: $-0.01, Percent Change: -1.20%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467168865","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467168865","pubTimestamp":1726456998,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","BK4125":"广播","BK7501":"新冠治疗股","DXB.AU":"DIMERIX LTD"},"translate_title":"Dimerix与英国罕见肾病登记处合作招募ACTION3三期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"DXB.AU":0.9},"content_text":"Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse.The trial aims to assess the efficacy and safety of the biopharmaceutical company's DMX-200 in treating a rare kidney condition called Focal Segmental Glomerulosclerosis, the filing stated. Recruitment is being done across 16 of the 19 planned countries, with a total recruitment target of 286 patients.Additionally, Dimerix received approval for its Investigational New Drug Application from the Thai Food and Drug Administration, clearing a prerequisite for trial initiation. It expects clinical sites to begin recruitment in Thailand in the coming weeks.The company's shares slipped past 1% in recent Monday trade.Price (AUD): $0.41, Change: $-0.01, Percent Change: -1.20%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}